



GOVERNMENT OF INDIA  
CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION (Headquarter)  
(Directorate General of Health  
Services) Ministry of Health & Family  
Welfare  
FDA Bhavan  
ITO, Kotla Road  
New Delhi - 110002 (Delhi)  
Phone No.: 91-11-  
23216367  
Fax No.: 91-11-23236973  
E-Mail : dci@nic.in

**File No. CT/24/000128**

To,  
M/s Bristol-Myers Squibb India Private Limited,  
One International Center, 6th Floor, Tower 1,  
Senapati Bapat Marg, Elphinstone (W),  
Maharashtra (India) – 400013

Sir,

With reference to your application No. GCT/CT04/FF/2024/46095 dated 04-Nov-2024, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled **“A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%”** Protocol no. **CA224-1093 version 2.0 dated 20 June 2024 with a total of up-to 100 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely: -

- (i) **The number of subjects shall be increased up to 100.**
- (ii) **More geographically distributed government sites shall be included in the study.**
- (iii) **PI shall be Medical oncologist only.**
- (iv) **Human biological samples i.e. Whole blood and Tumor Tissue Samples related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO.**
- (v) **ICMR approval should be submitted to the DCGI before initiation of genetic testing.**
- (vi) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- (vii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (viii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details

- of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (ix) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
  - (x) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
  - (xi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
  - (xii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
  - (xiii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
  - (xiv) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
  - (xv) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
  - (xvi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
  - (xvii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
  - (xviii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
  - (xix) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
  - (xx) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
  - (xxi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
  - (xxii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial;
  - (xxiii) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
  - (xxiv) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic

approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India) &  
Central Licensing Authority  
Stamp

**FORM CT-06**

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s Bristol-Myers Squibb India Pvt. Ltd., 6th Floor, Tower 1, One International Center, Senapati Bapat Marg, Elphinstone (West), Mumbai (India) - 400013 Telephone No.: 022-66288600 FAX: 022-66288700, 022-66288701 E-Mail: SONIKA.SHAH@BMS.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no. CA224-1093 version 2.0 dated 20 June 2024** in the below mentioned clinical trial sites [As per Annexure].

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date \_\_\_\_\_

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India) &  
Central Licensing Authority  
Stamp

**Note:** The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

**Annexure:**

Details of new drug or investigational new drug:

<b>Names of the new drug or investigational new drug</b>	Nivolumab+Relatlimab
<b>Therapeutic class:</b>	Anticancer
<b>Dosage form:</b>	Concentrate for Solution for Infusion
<b>Composition:</b>	Nivolumab =480.0000 milligram(mg) In House Specification Active Relatlimab =480.0000 milligram(mg) In House Specification Active
<b>Indications:</b>	Non-small cell lung cancer

**Annexure:**

Details of clinical trial site:

<b>Names and address of clinical trial site</b>	<b>Ethics committee details</b>	<b>Name of investigator</b>
Narayana Superspeciality Hospital, Narayana Superspeciality Hospital, 120-1, Andul Road Howrah West Bengal - 711103	NSH Ethics Committee Narayana Superspeciality Hospital, 120/1, Andul Road, Howrah - 711103, West Bengal, India  ECR/1006/Inst/WB/2018/RR-21	Dr Chandrakanth M V
All India Institute Of Medical Sciences AIIMS, All India Institute Of Medical Sciences Room no. 245, Second floor,B.R.A IRCH building, AIIMS Hospital, Ansari Nagar East, New Delhi New Delhi Delhi -110029	Institute Ethics Committee Institute Ethics Committee All India Institute Of Medical Sciences, Old OT Block, first floor, Room no.102, AIIMS Hospital, Ansari Nagar, New Delhi, Delhi-110029, India  ECR/538/Inst/DL/2014/RR-20	Dr Prabhat Singh Malik
Regional Cancer Centre, Regional Cancer Centre, Medical Oncology Department, Medical college campus, Thiruvananthapuram Kerala - 695011	Human Ethics Committee Regional Cancer Centre, Medical Oncology Department, Medical college campus, Thiruvananthapuram-695011, Kerala, India  ECR/21/Inst/Ker/2013/RR-19	Dr Anoop T M
Manipal Hospital, Manipal hospital, 98, Old Airport Road Bangalore Karnataka - 560017	Ethics Committee of Manipal Hospitals Ethics Committee of Manipal hospitals, Manipal hospital, #98, Old Airport Road, Bangalore - 560017, Karnataka, India  ECR/34/Inst/KA/2013/RR-24	Dr Amit Rauthan

<p>Rajiv Gandhi Cancer Institute and Research Centre, Rajiv Gandhi Cancer Institute and Research Centre, D-18, Sir Chotu Ram Marg, Rohini Institutional Area, Sector - 5, Rohini, Delhi Delhi - 110085</p>	<p>Institutional Review Board Institutional Review Board D-18, Rajiv Gandhi Cancer Institute and Research Centre, Sir Chotu Ram Marg, Rohini Institutional Area, Sector V, Rohini, New Delhi, Delhi -110085, India</p> <p>ECR/10/Inst/DC/2013/RR-19</p>	<p>Dr Ullas Batra</p>
<p>Tata Memorial Hospital, Tata Memorial Hospital OPD no-204, 2nd floor, Homi Bhabha Block, Tata Memorial Center, Dr Ernest Borges Road Parel, Mumbai Maharashtra - 400012</p>	<p>IRB-I and IRB-II IRB Office, Main Building, 3rd floor, Tata Memorial Hospital Parel, Mumbai-400012, Maharashtra, India</p> <p>ECR/170/Inst/MH/2013/RR-22 ECR/414/Inst/MH/2013/RR-19</p>	<p>Dr Kumar Prabhash</p>

\*\*\*\*\*